Recent Quotes (30 days)

You have no recent quotes
chg | %

Medicure Inc.  

(Public, CVE:MPH)   Watch this stock  
Find more results for CVE:MPH.H
+0.01 (0.53%)
Apr 1 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.91 - 1.92
52 week 0.80 - 3.15
Open 1.92
Vol / Avg. 4,610.00/11,982.00
Mkt cap 23.95M
P/E     -
Div/yield     -
EPS 0.00
Shares 12.42M
Beta 0.67
Inst. own 4%

Key stats and ratios

Q3 (Aug '14) 2014
Net profit margin 63.40% -32.45%
Operating margin 21.77% 3.26%
EBITD margin - 14.37%
Return on average assets 117.33% -46.62%
Return on average equity - -
Employees 4 -
CDP Score - -


2-1250 Waverley St
+1-204-4877412 (Phone)
+1-204-4889823 (Fax)

Website links


Medicure Inc. is a Canada-based pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company�s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. The Company�s primary, non-AGGRASTAT research and development activity is TARDOXAL for the treatment of Tardive Dyskinesia (TD). AGGRASTAT, a glycoprotein GP IIb or IIIa receptor antagonist, is used for the treatment of acute coronary syndrome (ACS), including unstable angina, which is characterized by chest pain when one is at rest, and non-Q-wave myocardial infarction. American Cardio Therapeutics Inc., a Company that is 49% owned by Medicure Pharma Inc.

Officers and directors

Albert D. Friesen Ph.D. Chairman of the Board, Chief Executive Officer
Age: 67
Dawson J. Reimer President, Chief Operating Officer
Age: 43
James F. Kinley C.A. Chief Financial Officer, Secretary
Age: 36
Brent Fawkes Director
Gerald P. McDole Independent Director
Age: 74
Arnold Naimark Independent Director
Age: 81
Peter Quick Independent Director
Age: 58